Connect with us


Why Mesoblast might be the best ASX healthcare growth share to own right now – Motley Fool Australia

The Mesoblast share price has skyrocketed 260% since March. Here we look at the key drivers behind the gains and whether Mesoblast is a buy.



post featured image

ASX junior pharmaceutical company Mesoblast Limited(ASX: MSB) is one of the few companies to have delivered substantial gains to its shareholders during 2020. While big name healthcare shares like Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL) have struggled throughout the COVID-19 pandemic, the Mesoblast share price has risen over 80% so far this year. It is also up an astounding 263% since bottoming out at $1.02 back in late March.
What’s been driving the Mesoblast share price?

Click here to view the original article.